Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


09.12.2024

2 Ann Oncol
5 Ann Surg Oncol
3 Anticancer Res
1 BMC Cancer
1 BMJ
1 Breast Cancer
4 Breast Cancer (Dove Med Press)
5 Breast Cancer Res
3 Breast Cancer Res Treat
4 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
2 Clin Breast Cancer
1 Clin Med Insights Oncol
1 Curr Treat Options Oncol
2 Eur J Surg Oncol
1 Exp Cell Res
1 Gene
1 Histopathology
1 Int J Cancer
1 Int J Oncol
1 J Biol Chem
1 J Clin Oncol
1 J Nucl Med
1 J Surg Oncol
1 Lancet Oncol
2 Nature
1 Oncogene
1 PLoS Med
7 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Oncol

  1. GOETZ MP, Andre V, Johnston SRD
    Response to letters to the Editor on 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3'.
    Ann Oncol. 2024;35:1202-1204.
    PubMed        

  2. CURIGLIANO G, Burstein HJ, Gnant M, Loibl S, et al
    Corrigendum to "Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023": [Annals of Oncology 34 (2023) 970-986].
    Ann Oncol. 2024 Dec 2:S0923-7534(24)04882-8. doi: 10.1016/j.annonc.2024.
    PubMed        


    Ann Surg Oncol

  3. SHIM V, Karlea A, Brenman LM, Gul J, et al
    ASO Visual Abstract: Impact of Mainstream Germline Genetic Testing with Expanded Eligibility for Early Stage Breast Cancer Patients in a Large Integrated Health System.
    Ann Surg Oncol. 2024 Dec 4. doi: 10.1245/s10434-024-16559.
    PubMed        

  4. YI JP, Yoon CI, Lim SH, Choi H, et al
    Prognosis of Patients with Breast Cancer Following Delayed Diagnosis During the COVID-19 Pandemic: A Real-World Cohort Study.
    Ann Surg Oncol. 2024 Dec 4. doi: 10.1245/s10434-024-16645.
    PubMed         Abstract available

  5. LAWS A, Leonard S, Vincuilla J, Parker T, et al
    Risk of Surgical Overtreatment in cN1 Breast Cancer Patients who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD.
    Ann Surg Oncol. 2024 Dec 4. doi: 10.1245/s10434-024-16625.
    PubMed         Abstract available

  6. WINER LK, Williams AD
    ASO Author Reflections: Beyond the Binary: Using IHC Status to Predict Response to Neoadjuvant Therapy in HER2+ Early-Stage Breast Cancer.
    Ann Surg Oncol. 2024 Dec 2. doi: 10.1245/s10434-024-16606.
    PubMed        

  7. CABIOGLU N, Karanlik H, Igci A, Muslumanoglu M, et al
    Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
    Ann Surg Oncol. 2024 Dec 2. doi: 10.1245/s10434-024-16472.
    PubMed         Abstract available


    Anticancer Res

  8. OZCIVICI E, Mese G
    Comprehensive Analysis of GJB1 in Breast Cancer: Its Implications in Survival and Molecular Mechanisms.
    Anticancer Res. 2024;44:5379-5391.
    PubMed         Abstract available

  9. SUGANUMA N, Saito N, Yasukawa M, Yamanaka T, et al
    Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines.
    Anticancer Res. 2024;44:5187-5192.
    PubMed         Abstract available

  10. SUGANUMA N, Matsubara Y, Takahashi A, Yamanaka T, et al
    Impact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.
    Anticancer Res. 2024;44:5225-5230.
    PubMed         Abstract available


    BMC Cancer

  11. BOAITEY GA, Martini R, Stonaker B, Bonsu EO, et al
    Patterns of breast cancer locoregional relapse, metastasis, and subtypes in Ghana.
    BMC Cancer. 2024;24:1485.
    PubMed         Abstract available


    BMJ

  12. ROBINSON A
    Advances in breast cancer and bowel cancer treatments ... and other research.
    BMJ. 2024;387:q2699.
    PubMed        


    Breast Cancer

  13. MORITA M, Tsunashima R, Yoshinami T, Ishida M, et al
    A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients.
    Breast Cancer. 2024 Dec 4. doi: 10.1007/s12282-024-01656.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  14. HAN X, Jiang D, Zhu C, Li D, et al
    Efficacy and Survival Analysis of Radiotherapy for Internal Mammary Lymph Nodes After Modified Radical Mastectomy for T(1-3)N(3)M(0) the Lateral Quadrant Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:811-823.
    PubMed         Abstract available

  15. ZHANG Y, Yang M, Wang Y, Zhao J, et al
    Identification and Validation of circDOCK1/miR-138-5p/GRB7 Axis for Promoting Breast Cancer Progression.
    Breast Cancer (Dove Med Press). 2024;16:795-810.
    PubMed         Abstract available

  16. CHANG Y, Du R, Xia F, Xu X, et al
    Dysregulation of Fatty Acid Metabolism in Breast Cancer and Its Targeted Therapy.
    Breast Cancer (Dove Med Press). 2024;16:825-844.
    PubMed         Abstract available

  17. ZHAO F, Zhang H
    Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients.
    Breast Cancer (Dove Med Press). 2024;16:845-853.
    PubMed         Abstract available


    Breast Cancer Res

  18. DE LA CRUZ P, McAdams J, Morales Aquino M, Fernandez AI, et al
    NF-kappaB associated markers of prognosis in early and metastatic triple negative breast cancer.
    Breast Cancer Res. 2024;26:175.
    PubMed         Abstract available

  19. COUNCELL KA, Polcari AM, Nordgren R, Skolarus TA, et al
    Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study.
    Breast Cancer Res. 2024;26:176.
    PubMed         Abstract available

  20. DEBELJAK M, Cho S, Downs BM, Considine M, et al
    Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.
    Breast Cancer Res. 2024;26:178.
    PubMed         Abstract available

  21. LEE DN, Li Y, Olsson LT, Hamilton AM, et al
    Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers.
    Breast Cancer Res. 2024;26:177.
    PubMed         Abstract available

  22. TERRY MB, English DR, Freudenheim JL, Lauby-Secretan B, et al
    Alcohol cessation and breast cancer risk stratified by hormone receptor status.
    Breast Cancer Res. 2024;26:179.
    PubMed         Abstract available


    Breast Cancer Res Treat

  23. RUGO HS, Campbell M, Yau C, Jo Chien A, et al
    Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555.
    PubMed         Abstract available

  24. LEONE JP, Leone J, Hassett MJ, Freedman RA, et al
    Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study.
    Breast Cancer Res Treat. 2024 Dec 2. doi: 10.1007/s10549-024-07562.
    PubMed         Abstract available

  25. DI LEONE A, Filippone A, Maggiore C, Rossi MM, et al
    The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study.
    Breast Cancer Res Treat. 2024 Dec 4. doi: 10.1007/s10549-024-07553.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  26. HUANG X, Lott PC, Hu D, Zavala VA, et al
    Evaluation of multiple breast cancer polygenic risk score panels in women of Latin American heritage.
    Cancer Epidemiol Biomarkers Prev. 2024 Dec 3. doi: 10.1158/1055-9965.EPI-24-1247
    PubMed         Abstract available

  27. POURALI G, Toriola AT
    The Untapped Opportunities of Addressing Lifecourse Growth in Mammographic Breast Density and Breast Cancer Prevention in Non-Hispanic Black Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1541-1543.
    PubMed         Abstract available

  28. NABI O, Liu Y, Struthers J, Lian M, et al
    The Role of Residential Segregation in Treatment and Outcomes of Ductal Carcinoma In Situ of the Breast.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1633-1639.
    PubMed         Abstract available

  29. BIGHAM Z, Holder EX, Rodday AM, Breeze JL, et al
    Lifecourse Growth and Development Determinants of Mammographic Density in Black Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1640-1650.
    PubMed         Abstract available


    Cancer Res

  30. FRIELING JS, Lynch CC
    Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt.
    Cancer Res. 2024;84:3917-3918.
    PubMed         Abstract available


    Clin Breast Cancer

  31. BATTAIOTTO E, d'Ambrosio S, Trapani D, Curigliano G, et al
    Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?
    Clin Breast Cancer. 2024 Nov 12:S1526-8209(24)00301.
    PubMed         Abstract available

  32. DAUNGSUPAWONG H, Wiwanitkit V
    Madarosis Among Breast Cancer Survivors: Correspondence.
    Clin Breast Cancer. 2024 Nov 8:S1526-8209(24)00298.
    PubMed        


    Clin Med Insights Oncol

  33. WEI J, Jiao F, Wang X, Qiao Y, et al
    High Expression of ZNF208 Predicts Better Prognosis and Suppresses the Tumorigenesis of Breast Cancer.
    Clin Med Insights Oncol. 2024;18:11795549241301341.
    PubMed         Abstract available


    Curr Treat Options Oncol

  34. BENVENUTI C, Grinda T, Rassy E, Dixon-Douglas J, et al
    Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer - A Clinical Review.
    Curr Treat Options Oncol. 2024 Nov 30. doi: 10.1007/s11864-024-01259.
    PubMed         Abstract available


    Eur J Surg Oncol

  35. MITCHELL MP, Shaitelman SF, Smith BD, Krishnamurthy S, et al
    Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy.
    Eur J Surg Oncol. 2024;50:108613.
    PubMed         Abstract available

  36. GENNARO M, Mariani L, Palassini E, Stacchiotti S, et al
    Timeline of surgery in localized angiosarcoma of the breast: Improving outcome following multidisciplinary treatment optimization.
    Eur J Surg Oncol. 2024;50:108699.
    PubMed         Abstract available


    Exp Cell Res

  37. AL-NOSHOKATY TM, El-Sayyad GS, Abdelhamid R, Mansour A, et al
    Long non-coding RNAs and their role in breast cancer pathogenesis and drug resistance: Navigating the non-coding landscape review.
    Exp Cell Res. 2024;444:114365.
    PubMed         Abstract available


    Gene

  38. LI Y, Gao H
    Investigation and validation of neurotransmitter receptor-related biomarkers for forecasting clinical outcomes and immunotherapeutic efficacy in breast cancer.
    Gene. 2024;937:149135.
    PubMed         Abstract available


    Histopathology

  39. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    PubMed         Abstract available


    Int J Cancer

  40. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35274.
    PubMed         Abstract available


    Int J Oncol

  41. LEE WX, Yeo BS, Mahmud R, Tan GC, et al
    MicroRNAs and their role in breast cancer metabolism (Review).
    Int J Oncol. 2025;66:7.
    PubMed         Abstract available


    J Biol Chem

  42. MASSEY S, Kongchan N, Gao Y, Chaudhury A, et al
    PKC-mediated phosphorylation governs the stability and function of CELF1 as a driver of EMT in breast epithelial cells.
    J Biol Chem. 2024;300:107826.
    PubMed         Abstract available


    J Clin Oncol

  43. PUSZTAI L, Hoag JR, Albain KS, Barlow WE, et al
    Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
    J Clin Oncol. 2024 Dec 2:JCO2401507. doi: 10.1200/JCO-24-01507.
    PubMed         Abstract available


    J Nucl Med

  44. WEEKS JK, Pantel AR, Gitto SB, Liu F, et al
    [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
    J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627.
    PubMed         Abstract available


    J Surg Oncol

  45. ROCHLIN DH, Matros E, Shamsunder MG, Rubenstein R, et al
    Plastic surgery market share of breast reconstructive procedures: An analysis of two nationwide databases.
    J Surg Oncol. 2023;128:1064-1071.
    PubMed         Abstract available


    Lancet Oncol

  46. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2024;25:e629-e638.
    PubMed         Abstract available


    Nature

  47. PETRIC HOWE N, Bates E
    Why breast cancer treatments might work best just after your period.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-03986.
    PubMed        

  48. INGMAN WV
    What is the best time of the month to treat breast cancer?
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-03847.
    PubMed        


    Oncogene

  49. TANG T, Yang T, Xue H, Liu X, et al
    Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03237.
    PubMed         Abstract available


    PLoS Med

  50. DUNN MR, Li D, Emerson MA, Thompson CA, et al
    A latent class assessment of healthcare access factors and disparities in breast cancer care timeliness.
    PLoS Med. 2024;21:e1004500.
    PubMed         Abstract available


    PLoS One

  51. WASSIE M, Zegeye AF, Aemro A, Terefe B, et al
    Awareness and its determinant factors towards breast examination to detect breast cancer among reproductive age women in Kenya: Multi level analysis of the recent demographic and health survey data.
    PLoS One. 2024;19:e0314700.
    PubMed         Abstract available

  52. JHA A, Chaudhary RK, Shrivastav S, Khanal U, et al
    Ultrasonographic and pathological correlation of asymmetric retroareolar density on mammogram.
    PLoS One. 2024;19:e0301180.
    PubMed         Abstract available

  53. LOKTIONOVA MV, Mohammadian M, Choopani R, Kheiri S, et al
    Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: A comprehensive systematic review and meta-analysis.
    PLoS One. 2024;19:e0314565.
    PubMed         Abstract available


  54. Correction: BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images.
    PLoS One. 2024;19:e0315419.
    PubMed         Abstract available

  55. CAPAR A, Ekinci DA, Ertano M, Niazi MKK, et al
    An interpretable framework for inter-observer agreement measurements in TILs scoring on histopathological breast images: A proof-of-principle study.
    PLoS One. 2024;19:e0314450.
    PubMed         Abstract available

  56. DONG F, Li J, Wang J, Yang X, et al
    Diagnostic performance of DCE-MRI radiomics in predicting axillary lymph node metastasis in breast cancer patients: A meta-analysis.
    PLoS One. 2024;19:e0314653.
    PubMed         Abstract available

  57. SCHRODER AK, Loy CJ, Aiala F, Rafique J, et al
    miR-379-5p affects breast cancer cell behavior by targeting UBE2E3 ubiquitin conjugating enzyme.
    PLoS One. 2024;19:e0310315.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  58. MATSUZAKI T, Fujii M, Noro H, Togo S, et al
    Simultaneous visualization of membrane fluidity and morphology defines adhesion signatures of cancer cells.
    Proc Natl Acad Sci U S A. 2024;121:e2412914121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.